Key Points
- Benjamin Machinas Beneski, SVP, sold 7,132 shares of Allogene on March 2 at an average of $2.60 for $18,543.20, trimming his stake by 3.39% to 203,040 shares; he also sold 7,549 shares on Feb 2 at $1.73.
- Allogene (NASDAQ:ALLO) traded around $2.32 mid-day, has a market cap near $521M, and a one‑year range of $0.86–$2.80 with 50/200‑day SMAs of $1.78 and $1.44.
- Analysts hold a “Moderate Buy” consensus with an average target of $8.40 (including recent upgrades and a UBS buy rating), and institutional investors own about 83.6% of the stock.
Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) SVP Benjamin Machinas Beneski sold 7,132 shares of Allogene Therapeutics stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $2.60, for a total value of $18,543.20. Following the transaction, the senior vice president directly owned 203,040 shares of the company's stock, valued at $527,904. This trade represents a 3.39% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Benjamin Machinas Beneski also recently made the following trade(s):
- On Monday, February 2nd, Benjamin Machinas Beneski sold 7,549 shares of Allogene Therapeutics stock. The shares were sold at an average price of $1.73, for a total transaction of $13,059.77.
Allogene Therapeutics Stock Performance
NASDAQ:ALLO traded down $0.21 during mid-day trading on Thursday, hitting $2.32. 2,888,999 shares of the company's stock traded hands, compared to its average volume of 5,852,930. The company has a market cap of $521.37 million, a PE ratio of -2.37 and a beta of 0.50. The firm's 50 day simple moving average is $1.78 and its 200 day simple moving average is $1.44. Allogene Therapeutics, Inc. has a 1 year low of $0.86 and a 1 year high of $2.80.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of ALLO. Savant Capital LLC purchased a new position in shares of Allogene Therapeutics during the 3rd quarter worth about $27,000. Russell Investments Group Ltd. increased its position in Allogene Therapeutics by 11,159.8% during the third quarter. Russell Investments Group Ltd. now owns 21,844 shares of the company's stock worth $27,000 after purchasing an additional 21,650 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its position in Allogene Therapeutics by 5,267.6% during the third quarter. Caitong International Asset Management Co. Ltd now owns 24,047 shares of the company's stock worth $30,000 after purchasing an additional 23,599 shares during the last quarter. Mercer Global Advisors Inc. ADV purchased a new position in Allogene Therapeutics during the third quarter worth approximately $30,000. Finally, Brighton Jones LLC boosted its holdings in shares of Allogene Therapeutics by 81.6% in the 3rd quarter. Brighton Jones LLC now owns 25,168 shares of the company's stock valued at $31,000 after purchasing an additional 11,311 shares during the last quarter. Institutional investors and hedge funds own 83.63% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently issued reports on the company. Wall Street Zen raised Allogene Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday, February 22nd. Citigroup raised Allogene Therapeutics from a "market perform" rating to an "outperform" rating in a report on Friday, January 9th. Citizens Jmp raised Allogene Therapeutics from a "market perform" rating to an "outperform" rating and set a $5.00 price objective on the stock in a research note on Friday, January 9th. Finally, UBS Group initiated coverage on shares of Allogene Therapeutics in a research note on Wednesday, January 7th. They issued a "buy" rating and a $8.00 target price for the company. Ten equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Allogene Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $8.40.
Read Our Latest Research Report on Allogene Therapeutics
About Allogene Therapeutics
(
Get Free Report)
Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.
The company's pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
